Tivoxen 1.34Mg Cap (Tivozanib Cap)

Introduction:

Tivoxen 1.34 mg, manufactured by Everest Pharmaceuticals Ltd and supplied by Orio Pharma, is a highly effective targeted therapy used for the treatment of advanced renal cell carcinoma (RCC). Containing Tivozanib, Tivoxen 1.34 mg is a potent inhibitor of vascular endothelial growth factor (VEGF) receptors, which are crucial for the growth and spread of cancer cells. This medication is designed to slow the progression of RCC by inhibiting tumor angiogenesis, offering a significant treatment option for patients with advanced kidney cancer.Dosage and Administration:

The recommended dosage of Tivoxen 1.34 mg is one capsule taken once daily for 21 days, followed by a 7-day break (a total 28-day cycle). This cycle may be repeated as long as the patient continues to benefit from the treatment. The capsule should be swallowed whole with water, and it can be taken with or without food. It is important for patients to adhere to their healthcare provider's instructions and follow the prescribed dosing schedule. Regular monitoring of the patient's health, including liver function and blood pressure, is necessary to assess the response to therapy and manage any potential side effects.

Benefits of Tivoxen 1.34 mg:

• Targeted Cancer Therapy: Tivoxen 1.34 mg provides a precision treatment for patients with advanced RCC, directly targeting the VEGF receptors that drive tumor growth and spread.
• Improved Progression-Free Survival: Clinical evidence shows that Tivoxen 1.34 mg significantly delays disease progression, offering hope for patients with advanced kidney cancer.
• Convenient Oral Administration: The once-daily oral dosing of Tivoxen 1.34 mg ensures ease of use and supports patient adherence to the treatment regimen.
• Well-Tolerated: Tivoxen 1.34 mg is generally well-tolerated, with a safety profile that supports its use in long-term treatment under proper medical supervision.